Solasia Pharma K.K. Company Description

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries.

The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting.

It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer.

The company was founded in 2006 and is based in Tokyo, Japan.

Solasia Pharma K.K.

Country	Japan
Founded	2006
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	23
CEO	Yoshihiro Arai

Contact Details

Address: Sumitomo Fudosan Shiba-Koen Tower Tokyo, 105-0011 Japan
Phone	81 3 5843 8045
Website	solasia.co.jp

Stock Details

Ticker Symbol	4597
Exchange	Tokyo Stock Exchange
Fiscal Year	January - December
Reporting Currency	JPY
ISIN Number	JP3436500007
SIC Code	2836

Key Executives

Name	Position
Yoshihiro Arai	Chief Executive Officer
Toshio Miyashita	Chief Financial Officer